ACOs and Value-Based Care Organizations
Prevent Falls. Lower Costs. Increase Shared Savings.
Vestibular dysfunction and balance impairment can be a ticking timebomb: one fall can trigger a costly cascade of emergency care, hospitalization, surgery, post-acute care, rehabilitation, and loss of independence, driving a dramatic increase in total cost of care.
What if you could reduce the risk before the fall ever happens?
GyroStim offers an extraordinary opportunity to do just that. By deploying FDA-cleared, FDA Breakthrough Device-designated vestibular technology upstream at the point of care, GyroStim can rapidly improve vestibular function and balance, preserve mobility, extend independence, and reduce fall risk, helping prevent the costly downstream cascade of care before it ever begins.
FDA-Recognized Breakthrough Technology for Vestibular Dysfunction
GyroStim is 'intended to assist in the treatment of balance disorders and vestibular dysfunction' and designated by the FDA as a Breakthrough Device, placing vestibular care and fall prevention at the very center of its regulatory distinction. In retrospective clinical analyses, GyroStim was associated with up to a fivefold faster rate of improvement than standard of care alone across multiple validated balance measures.
5X Faster Improvement → Earlier Fall-Risk Reduction → Lower Downstream Costs
For ACOs and other Value-Based Care organizations, the clinical and economic implications can be substantial. Faster improvement in vestibular function and balance creates an opportunity to prevent falls and the costly cascade of care associated with serious falls before they happen. At population scale, even modest reductions in fall-related utilization have the potential to eliminate substantial avoidable healthcare costs, materially lower total cost of care, and generate significant new shared savings.
Based on clinical data provided by Kim Fox, DPT, Clinical Director & Founder, AVORA Health, Asheville, NC.
Prevent Falls at Their Source: Balance and Vestibular Dysfunction
Falls are often the end result of underlying impairments in balance, vestibular function, sensory integration, and postural control. For ACOs and other Value-Based Care organizations, addressing these underlying functional deficits as soon as they are identified represents a powerful, high-value opportunity to reduce fall risk at its source, before it becomes one of healthcare’s most costly and consequential events.
Improve Balance Upstream→ Reduce Costs Downstream
By targeting balance disorders and vestibular dysfunction, GyroStim provides an upstream approach to improving stability, preserving mobility, and extending independence, while expanding treatment access to frail and highly impaired patients who may be unable to participate effectively in conventional rehabilitation. Preventing even a fraction of serious falls has the potential to avoid the costly cascade of emergency care, hospitalization, surgery, rehabilitation, post-acute care, and long-term loss of independence.
How Much Shared Savings Could GyroStim Add to Your Next Performance Payment?
Scalable from individual clinics to large, multi-site healthcare systems, GyroStim provides a pathway to translate better vestibular, balance, and functional outcomes across patient populations into fewer costly downstream events, lower total cost of care, and greater shared savings, ultimately increasing the potential value of your next performance payment.
More than a medical device,
GyroStim transforms better clinical outcomes into greater shared savings.
GyroStim combines FDA clearance with FDA Breakthrough Device designation for neurotechnology specifically cleared to treat balance disorders and vestibular dysfunction, placing GyroStim directly at the intersection of vestibular care and fall-risk reduction.
For VBC organizations, that creates a powerful opportunity to improve outcomes, reduce avoidable utilization, lower total cost of care, and increase shared savings.
GyroStim creates value by addressing vestibular dysfunction, balance impairment, and fall risk before they explode into costly downstream care. Better balance and functional outcomes can improve stability, preserve mobility and independence, and help reduce the risk of falls that lead to emergency care, hospitalization, rehabilitation, post-acute care, and other costly utilization.
For VBC organizations, the economics are powerful: improve function upstream, reduce costs downstream. At population scale, even modest reductions in fall-related utilization have the potential to generate substantial savings, making GyroStim a strategic capital investment capable of delivering better outcomes, lower total cost of care, and greater shared savings.
-
Better patient outcomes
-
Increased patient throughput
-
Lower total cost of care
-
Improved utilization of personnel and infrastructure
-
Greater shared savings
-
Stronger return on capital investment
-
Healthcare's most resource-intensive patient populations represent one of the greatest opportunities to improve both clinical and financial performance under Value-Based Care. GyroStim helps transform these high-cost populations into high-value opportunities by improving outcomes, reducing total cost of care, and increasing shared savings.
Target populations include:
-
Concussion and mild traumatic brain injury (mTBI)
-
Vestibular dysfunction and balance disorders
-
Fall-risk and older adult populations
-
Stroke and neurological impairment
-
Chronic neurodegenerative and post-viral conditions
Many of these patients are among the most difficult to rehabilitate. Severe balance impairment, neurological dysfunction, cognitive deficits, frailty, and fatigue often limit their ability to participate effectively in conventional rehabilitation—contributing to prolonged recovery, preventable complications, and escalating healthcare costs.
GyroStim was engineered to overcome these limitations. By expanding access to advanced multimodal rehabilitation for many low-functioning patients, GyroStim has the potential to accelerate recovery, reduce falls and downstream complications, lower total cost of care, and transform one of healthcare's highest-cost patient populations into one of its greatest opportunities for value creation and shared savings.
-
GyroStim helps Value-Based Care organizations:
-
Differentiate with FDA Breakthrough Device-Designated Neurotechnology
-
Create a Powerful, Marketable Story of Clinical Innovation
-
Attract Patients, Providers, and Referral Partners
-
Improve Patient Satisfaction and Engagement
-
Strengthen Referral Pathways and Network Loyalty
-
Reduce Patient Leakage to Competing Health Systems
-
Preserve Revenue and Expand Shared Savings Opportunities
In Value-Based Care, differentiation is about more than reputation. GyroStim gives healthcare organizations something increasingly difficult to achieve: a truly differentiated clinical capability and a powerful story to tell about it.
FDA-cleared and FDA Breakthrough Device-designated, GyroStim provides a highly visible platform for organizations to showcase clinical innovation, elevate market leadership, attract patients and referral partners, and keep more care within the network, turning clinical differentiation into strategic and economic advantage.
-
The economic advantage is simple: improve function faster, reduce risk earlier, and spend less on costly downstream care. Faster improvement creates opportunities to reduce:
-
Time Spent at Elevated Risk for Falls
-
Extended Treatment and Rehabilitation Cycles
-
Repeat Visits and Ongoing Clinical Management
-
Downstream Healthcare Utilization
-
Fall-Related Emergency, Hospital, and Post-Acute Care
-
Total Cost per Episode of Care
Vestibular dysfunction can be a ticking timebomb for Value-Based Care. The longer balance impairment and fall risk persist, the longer patients remain vulnerable to falls and associated costly complications.
Faster improvement means shorter care cycles, earlier reduction in fall risk, and less opportunity for downstream costs to accumulate. At population scale, that can translate into lower total cost of care and greater shared savings.
-
GyroStim has demonstrated recovery rates many times faster than conventional care, creating a compelling value proposition for Value-Based Care organizations.
-
Shorter episodes of care
-
Lower cost per episode
-
Increased clinical capacity
-
Greater patient access
-
Improved patient satisfaction
-
Reduced risk of preventable complications
-
Lower downstream healthcare utilization
-
More patients treated with the same clinical resources
-
Greater shared savings and financial performance
Every week removed from the recovery timeline creates value. Faster recovery reduces resource utilization, expands treatment capacity, lowers total cost of care, and enables healthcare organizations to treat more patients without increasing infrastructure or staffing.
Shorter episodes → Lower cost → Greater capacity → More patients treated → Higher shared savings.
In Value-Based Care, faster recovery doesn't simply improve efficiency—it multiplies value.
-
GyroStim complements existing rehabilitation strategies by extending—not replacing—the expertise of skilled clinicians. Its standardized, protocol-driven design enables healthcare organizations to scale cutting-edge rehabilitation across entire provider networks while preserving the flexibility of local clinical practice.
-
Standardized
-
Protocol-driven
-
Repeatable
-
Reproducible
-
Data-driven
-
Scalable
Whether deployed in hospitals, outpatient rehabilitation centers, specialty clinics, or integrated health systems, GyroStim integrates seamlessly into existing rehabilitation workflows while delivering consistent, high-quality multimodal neurorehabilitation through standardized treatment protocols and objective outcome measures.
The result is a scalable model of care that strengthens clinical consistency, operational efficiency, and Value-Based Care performance across the healthcare organization.
-
Many of the patients who need vestibular rehabilitation therapy the most are also the least able to participate in it. GyroStim was engineered to overcome this barrier by expanding access to advanced multimodal neurorehabilitation for patients with:
-
Vestibular dysfunction and balance disorders
-
Concussion and mild traumatic brain injury (mTBI)
-
Stroke and neurological impairment
-
Fall-risk and older adult populations
-
Chronic neurodegenerative and post-viral conditions
As the world’s only FDA-cleared, Breakthrough Device-designated multimodal neurorehabilitation system, GyroStim enables many low-functioning patients to access advanced, precisely controlled therapy far beyond what conventional rehabilitation alone can effectively deliver.
By expanding treatment capabilities for these challenging populations, GyroStim has the potential to accelerate functional improvement, reduce fall risk and downstream complications, lower healthcare utilization, and transform high-cost, difficult-to-treat populations into opportunities for better outcomes and greater economic value.
-
By improving balance and fall-risk measures up to 5X faster, GyroStim has the potential to reduce the time patients remain vulnerable to costly downstream events and prolonged healthcare utilization.
-
Reduced Fall Risk and Fall-Related Complications
-
Shorter Rehabilitation and Treatment Cycles
-
Reduced Need for Ongoing Clinical Management
-
Fewer Costly Downstream Complications
-
Reduced Emergency and Hospital Utilization
-
Lower Overall Healthcare Utilization
Every costly event avoided preserves healthcare resources, lowers total cost of care, and creates greater value for patients, providers, and VBC organizations.
-
Value-Based Care demands more than treatment—it demands measurable outcomes. GyroStim provides objective, quantifiable data that helps organizations demonstrate clinical improvement, validate quality, and support value-based reimbursement:
-
Objective functional outcomes
-
Real-time treatment metrics
-
Standardized, protocol-driven care
-
Quantifiable patient improvement
-
Quality reporting support
-
Value-based reimbursement documentation
-
Evidence for payer negotiations
Better data leads to better decisions, better outcomes, and greater value.
-
GyroStim is uniquely positioned to help healthcare organizations achieve the three outcomes that define success in Value-Based Care:
-
Better patient outcomes
-
Lower total cost of care
-
Greater shared savings
GyroStim's technological advantages align remarkably well with the objectives of Value-Based Care.
By improving vestibular function and balance faster, reducing fall-risk exposure and downstream utilization, increasing clinical efficiency, and improving patient satisfaction, GyroStim creates multiple pathways to clinical and economic value across the healthcare organization.
-
Proven safe.
Proven effective.
Proven transformative.
-
K220231: FDA-Cleared: for the treatment of balance disorders and vestibular dysfunction—common and often debilitating neurological conditions associated with head injury, numerous neurological disorders, and age-related neurological decline.
-
Safe: Exceeds all regulatory requirements - zero injuries since clinical applications began in 2010.
-
Effective: Up to 8x faster rehabilitation rate for concussion recovery than conventional therapies alone.
-
Accessible: Unlike traditional therapies, GyroStim is accessible to a broader range of patients—including those with severe physical or cognitive disabilities.
-
Transformative: GyroStim has transformed tens of thousands of lives since 2010, advancing neurological recovery, human performance, and quality of life around the world.
Transform Fall-Prevention Into Greater Shared Savings.
Let's talk! Learn how GyroStim can help your organization improve vestibular function and balance, reduce fall risk, prevent costly downstream events, lower total cost of care, and create greater shared savings.
Call us. We're here to help.
Or click below to schedule a call, arrange a virtual demonstration, or request more information.
